Filing Summary
Business Context and Reporting Period
Xeris Biopharma Holdings, Inc. filed a Form 8-K dated June 7, 2023, reporting the results of its Annual Meeting of Stockholders held on that date. The company is incorporated in Delaware and its common stock trades on The Nasdaq Global Select Market under the symbol XERS.
As of the April 12, 2023 record date, 137,309,116 shares of common stock were outstanding and entitled to vote.
Annual Meeting Results
| Proposal | Result | Vote Details |
|---|---|---|
| Election of Dawn Halkuff | Approved | 53,237,483 for; 4,428,497 withheld; 31,220,403 broker non-votes |
| Election of John Johnson | Approved | 42,931,137 for; 14,734,843 withheld; 31,220,403 broker non-votes |
| Election of Jeffrey Sherman | Approved | 51,327,413 for; 6,338,567 withheld; 31,220,403 broker non-votes |
| Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal 2023 | Approved | 87,826,099 for; 820,583 against; 239,701 abstain |
The elected Class II directors will serve until the 2026 Annual Meeting of Stockholders and until their successors are elected and qualified, or until earlier death, resignation, or removal.
Financial Metrics and Liquidity
This filing is limited to shareholder voting matters and does not report revenue, profit or loss, cash flow, margins, debt, liquidity, guidance, or other operating or financial metrics.
Material Changes, Outlook, and Risks
The filing does not disclose material changes to the company’s business, management outlook, contingencies, unusual items, or specific risks. No matters other than the director elections and auditor ratification were submitted to or voted on at the meeting.
Investor Verification Items
- Verify the elected Class II director terms and board composition in subsequent filings.
- Confirm Ernst & Young LLP’s continued appointment as the company’s independent registered public accounting firm for fiscal 2023.
- Review the company’s periodic reports for financial performance, liquidity, debt, operating outlook, and risk disclosures, which are not provided in this 8-K.
- Note the substantial broker non-vote totals in the director elections, particularly 31,220,403 for each nominee.